Radioimmunotherapy of micrometastases in lung with vascular targeted213Bi

[1]  S. Kennel,et al.  Vascular targeted radioimmunotherapy with 213Bi-An α-particle emitter , 1998 .

[2]  S. Kennel,et al.  Vascular targeted radioimmunotherapy with 213Bi--an alpha-particle emitter. , 1998, Nuclear medicine and biology.

[3]  D M Foster,et al.  Developing and testing integrated multicompartment models to describe a single-input multiple-output study using the SAAM II software system. , 1998, Advances in experimental medicine and biology.

[4]  S. Kennel,et al.  Optimizations of Radiolabeling of Immunoproteins with 213Bi , 1997 .

[5]  Grietje Molema,et al.  Tumor Infarction in Mice by Antibody-Directed Targeting of Tissue Factor to Tumor Vasculature , 1997, Science.

[6]  William Arbuthnot Sir Lane,et al.  Endostatin: An Endogenous Inhibitor of Angiogenesis and Tumor Growth , 1997, Cell.

[7]  S. Kennel,et al.  Vascular Targeting for Radioimmunotherapy with 213Bi , 1997 .

[8]  J. Krosl,et al.  The role of host lymphoid populations in the response of mouse EMT6 tumor to photodynamic therapy. , 1996, Cancer research.

[9]  K. Hillan,et al.  Complete inhibition of angiogenesis and growth of microtumors by anti-vascular endothelial growth factor neutralizing antibody: novel concepts of angiostatic therapy from intravital videomicroscopy. , 1996, Cancer research.

[10]  Erkki Ruoslahti,et al.  Organ targeting In vivo using phage display peptide libraries , 1996, Nature.

[11]  A. Gazdar,et al.  Up-regulation of endoglin on vascular endothelial cells in human solid tumors: implications for diagnosis and therapy. , 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.

[12]  L. Khawli,et al.  Identification of a monoclonal antibody, TV-1, directed against the basement membrane of tumor vessels, and its use to enhance the delivery of macromolecules to tumors after conjugation with interleukin 2. , 1995, Cancer research.

[13]  J. Folkman,et al.  Treatment of murine hemangioendotheliomas with the angiogenesis inhibitor AGM-1470. , 1995, Journal of pediatric surgery.

[14]  R. McLendon,et al.  Radioimmunotherapy of Neoplastic Meningitis in Rats Using an α-Particle-emitting Immunoconjugate , 1994 .

[15]  T. Waldmann,et al.  Radioimmunotherapy of Nude Mice Bearing a Human Interleukin 2 Receptor α-expressing Lymphoma Utilizing the α-emitting Radionuclide-conjugated Monoclonal Antibody 212Bi-anti-Tac , 1994 .

[16]  M. Brechbiel,et al.  Radioimmunotherapy of nude mice bearing a human interleukin 2 receptor alpha-expressing lymphoma utilizing the alpha-emitting radionuclide-conjugated monoclonal antibody 212Bi-anti-Tac. , 1994, Cancer research.

[17]  R. McLendon,et al.  Radioimmunotherapy of neoplastic meningitis in rats using an alpha-particle-emitting immunoconjugate. , 1994, Cancer research.

[18]  F. Burrows,et al.  Vascular targeting--a new approach to the therapy of solid tumors. , 1994, Pharmacology & therapeutics.

[19]  J. Humm,et al.  Morphological, biochemical, and molecular changes in endothelial cells after alpha-particle irradiation. , 1993, Radiation research.

[20]  Bing Li,et al.  Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo , 1993, Nature.

[21]  J. F. Briesmeister.  MCNP-A General Monte Carlo N-Particle Transport Code , 1993 .

[22]  S. Kennel,et al.  Targeted therapy of athymic mice bearing GW-39 human colonic cancer micrometastases with 131I-labeled monoclonal antibodies. , 1992, Cancer research.

[23]  M. Brechbiel,et al.  Effective α-Particle-mediated Radioimmunotherapy of Murine Leukemia , 1992 .

[24]  M. Brechbiel,et al.  Synthesis of C-functionalized trans-cyclohexyldiethylenetriaminepenta-acetic acids for labelling of monoclonal antibodies with the bismuth-212 α-particle emitter , 1992 .

[25]  S. Kennel,et al.  Rat monoclonal antibody distribution in mice: an epitope inside the lung vascular space mediates very efficient localization. , 1990, International journal of radiation applications and instrumentation. Part B, Nuclear medicine and biology.

[26]  L. Huang,et al.  Monoclonal antibody targeting of liposomes to mouse lung in vivo. , 1989, Cancer research.

[27]  Herbert Malamud,et al.  MIRD Primer for Absorbed Dose Calculations , 1989 .

[28]  S. Kennel,et al.  Quantitation of a murine lung endothelial cell protein, P112, with a double monoclonal antibody assay. , 1988, Laboratory investigation; a journal of technical methods and pathology.

[29]  Thomas F. Budinger,et al.  MIRD primer for absorbed dose calculations , 1988 .

[30]  J. Humm.  A microdosimetric model of astatine-211 labeled antibodies for radioimmunotherapy. , 1987, International journal of radiation oncology, biology, physics.

[31]  M Terzaghi-Howe,et al.  Inhibition of carcinogen-altered rat tracheal epithelial cell proliferation by normal epithelial cells in vivo. , 1987, Carcinogenesis.

[32]  J. Denekamp.  Vasculature as a Target for Tumour Therapy , 1984 .

[33]  I. Adamson,et al.  Lung injury induced by butylated hydroxytoluene: cytodynamic and biochemical studies in mice. , 1977, Laboratory investigation; a journal of technical methods and pathology.

[34]  J. Yuhas,et al.  Specific and nonspecific stimulation of resistance to the growth and metastasis of the line 1 lung carcinoma. , 1975, Cancer research.

[35]  S. Aaronson,et al.  In vitro cultivation of human tumors: establishment of cell lines derived from a series of solid tumors. , 1973, Journal of the National Cancer Institute.

[36]  L. F. Fajardo,et al.  Characteristics of a serially transplanted mouse mammary tumor and its tissue-culture-adapted derivative. , 1972, Journal of the National Cancer Institute.